Tag: DAPA-MI clinical trial

Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI

pharmanewsdaily- July 20, 2020

AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) ... Read More